Ischemic Injury and Ischemic Preconditioning in Diabetes

Summary

In this proof-of-concept study, forearm vulnerability to ischemic exercise is studied in patients with type 1 diabetes mellitus with and without prior ischemic preconditioning (short period of ischemia that protects against subsequent ischemic exercise). Annexin A5 scintigraphy is used to quantify subtle signs of mild and reversible forearm injury that results from ischemic exercise.

The following hypotheses are tested:

1. Patients with type 1 diabetes are not more vulnerable to ischemic injury as compared with previously studied healthy volunteers.
2. Ischemic preconidtioning is still present in patients with type 1 diabetes. Depending on the validity of hypothesis 2, the effect of short pharmacological interventions are studied on vulnerability to forearm ischemia/reperfusion injury in the absence or presence of local forearm ischemic preconditioning.

Conditions

• Diabetes Mellitus, Insulin-Dependent
• Ischemia-Reperfusion Injury

Interventions

PROCEDURE

Ischemic preconditioning

PROCEDURE

Forearm ischemic exercise

PROCEDURE

Annexin A5 scintigraphy

DRUG

Diazoxide

DRUG

glibenclamide

DRUG

adenosine

Sponsors & Collaborators

• Dutch Diabetes Fund

  collaborator UNKNOWN

• Radboud University Medical Center

  lead OTHER

Principal Investigators

• Richard Engbersen, MD · Radboud University Nijmegen Medical Centre; department of Pharmacology-Toxicology

• Gerard Rongen, MD, PhD · Radboud University Nijmegen Medical Centre; Department of Pharmacology-Toxicology

• Wim Oyen, MD, PhD · Radboud University Nijmegen Medical Centre; Department of Nuclear Medicine

• Marc Mol, MD, PhD · Canisius Wilhelmina Ziekenhuis Nijmegen; Department of Internal Medicine

• Paul Smits, MD, PhD · Radboud University Nijmegen Medical Centre; Department of Pharmacology-Toxicology

• B. Bravenboer, MD, PhD · Catharina Hospital Eindhoven, Dept. of Internal Medicine

Eligibility

Min Age

18 Years

Max Age

50 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2004-06-30

Completion

2005-05-31

Countries

• Netherlands

Study Locations